DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Aarti Pharmalabs Limited — Analysts/Institutional Investor Meet/Con. Call Updates

NSE 6 hrs ago·17 Aug 2026, 11:00 am

Aarti Pharmalabs

Aarti Pharmalabs has shared the transcript from its recent institutional investor meeting with the stock exchange. This disclosure allows investors to review the company's management commentary, future outlook, and strategic plans directly from the source.

This update is significant for investors as it provides clarity on the company's growth trajectory and operational roadmap. By understanding management's perspective, retail investors can better assess the firm's competitive positioning and long-term potential.

Investors should focus on the management's guidance regarding production capacity, export demand, and margin expansion. Keeping an eye on any forward-looking statements will be crucial for gauging the stock's future performance.